A composition of matter for an analgesia and its method of use is disclosed. The composition comprises selected single cobrotoxin molecule which is characterized by its high affinity binding to nicotinic acetylcholine receptors, rapid onset, and better safety profile comparing to a cobrotoxins complexes. The method of use is for the treatment of pain, especially for the treatment of refractory pain as associated with advanced cancer, rheumatoid arthritis, chronic neuropathic, migraine, and viral infections.

A homeopathic pain topical analgesic composition based on snake venom is disclosed. The study product also contained of Arnica montana, a homeopathic remedy most frequently used for fractures, bruises, and muscle strains due to its analgesic and anti-inflammatory effects. The composition also contained a penetrant component to enhance penetration of the ingredients as well as an analgesic/anti-inflammatory component. The snake venoms used may include those of Naja naja, Crotalus horridus and Lachesis muta. A clinical study of a product formulated in this way was effective in promoting relief from muscle pain and discomfort.

A homeopathic pain topical analgesic composition based on snake venom is disclosed. The study product also contained of Arnica montana, a homeopathic remedy most frequently used for fractures, bruises, and muscle strains due to its analgesic and anti-inflammatory effects. The composition also contained a penetrant component to enhance penetration of the ingredients as well as an analgesic/anti-inflammatory component. The snake venoms used may include those of Naja naja, Crotalus horridus and Lachesis muta. A clinical study of a product formulated in this way was effective in promoting relief from muscle pain and discomfort.

A protein with an activity of inhibiting angiogenesis and inflammation, and a specific structure, use, and preparation method thereof are provided. The protein can inhibit both angiogenesis and inflammation, and can prevent and alleviate ophthalmic diseases such as age-related macular degeneration (AMD), diabetic retinopathy (DR), and pterygium to some extent based on a dual action mechanism.

A composition of sterile cobra venom and a method for its oral administration to provide significant analgesic effects to a human and/or animal are disclosed. Such cobra venom compositions comprise a sterilized solution preserved by the addition of one or more suitable food-grade preservatives. The venom composition may be conveniently administered orally by means of a metered spray device.

Provided herein are compositions for preventing or treating muscle conditions such as muscle damage, injury, or atrophy. In some embodiments, the compositions comprise a prostaglandin E2 (PGE2) compound and a myotoxin. In some embodiments, the muscle damage, injury, or atrophy is the result of a nerve injury, a surgical procedure, or a traumatic injury. Methods of promoting muscle regeneration and methods of increasing muscle mass are also provided herein.

Provided herein are compositions for preventing or treating muscle conditions such as muscle damage, injury, or atrophy. In some embodiments, the compositions comprise a prostaglandin E2 (PGE2) compound and a myotoxin. In some embodiments, the muscle damage, injury, or atrophy is the result of a nerve injury, a surgical procedure, or a traumatic injury. Methods of promoting muscle regeneration and methods of increasing muscle mass are also provided herein.

Provided herein are compositions for preventing or treating muscle conditions such as muscle damage, injury, or atrophy. In some embodiments, the compositions comprise a prostaglandin E2 (PGE2) compound and a myotoxin. In some embodiments, the muscle damage, injury, or atrophy is the result of a nerve injury, a surgical procedure, or a traumatic injury. Methods of promoting muscle regeneration and methods of increasing muscle mass are also provided herein.

A pharmaceutical composition for preventing or treating inflammatory disease comprising snake venom is disclosed. More specifically, the pharmaceutical composition or quasi-drug includes venom of Agkistrodon piscivorus piscivorus or Naja melanoleuca as an active ingredient. A method for preventing or treating inflammatory disease includes administering the venom of Agkistrodon piscivorus piscivorus or Naja melanoleuca to a subject. The composition can increase the expression of C-C chemokine receptor type 1 (CCR1) in a mouse where skin ulcer is induced and thus has an excellent effect of treating skin ulcers, and thus can be effectively used for the treatment of skin ulcers, in particular Behcet's disease or Buerger's disease.

A pharmaceutical composition for preventing or treating inflammatory disease comprising snake venom is disclosed. More specifically, the pharmaceutical composition or quasi-drug includes venom of Agkistrodon piscivorus piscivorus or Naja melanoleuca as an active ingredient. A method for preventing or treating inflammatory disease includes administering the venom of Agkistrodon piscivorus piscivorus or Naja melanoleuca to a subject. The composition can increase the expression of C-C chemokine receptor type 1 (CCR1) in a mouse where skin ulcer is induced and thus has an excellent effect of treating skin ulcers, and thus can be effectively used for the treatment of skin ulcers, in particular Behcet's disease or Buerger's disease.